breast cancer - adjuvant

15 trials

breast cancer - HER2-positive

38 trials

breast cancer - HR positive

44 trials

breast cancer - triple negative

30 trials

metastatic/advanced - breast cancer

1 trials

see all

ATEMPT, 2021

breast cancer - adjuvant

trastuzumab emtasine plus endocrine therapy

Bachelot, 2022

breast cancer - adjuvant

everolimus

DESTINY-Breast04, 2022

metastatic/advanced - breast cancer (mBC)

trastuzumab deruxtecan

NCT00454805, 2013

la/mBC - HR-positive - 1st line (L1)

cediranib plus fulvestrant

AKT inhibitor

5 trials

antibody–drug conjugate

14 trials

aurora kinase inhibitors

1 trials

biguanide

1 trials

celecoxib plus endocrine therapy

1 trials

chemotherapy

1 trials

cyclin inhibitor

19 trials

HDAC inhibitor

3 trials

HER inhibitor

34 trials

IGF-1R inhibitors

2 trials

immune chekpoint inhibitors

23 trials

Immunostimulant

1 trials

inetetamab plus vinorelbine

1 trials

mTOR inhibitors

3 trials

phosphoinositide 3-kinase (PI3K) inhibitor

10 trials

poly ADP-ribose polymerase (PARP) inhibitor

6 trials

target therapy

1 trials

VEGF(R) inhibitor

2 trials